CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

被引：124
|
作者：
Maisey, NR [1 ]
Norman, AR [1 ]
Hill, A [1 ]
Massey, A [1 ]
Oates, J [1 ]
Cunningham, D [1 ]
机构：
[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England
来源：
BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 07期
关键词：
pancreatic cancer; CA19-9; prognosis; chemotherapy;
D O I：
10.1038/sj.bjc.6602760
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95% CI: 1.3 - 2.5, P = 0.0004). The 1-year OS was 19 and 46%, respectively, for patients with a baseline CA19-9 above or below the median value. A fall of 20% in CA19-9 level from baseline was an independent prognostic factor for OS ( HR 1.9; 95% CI: 1.1 - 3.4, P = 0.019).
引用
收藏
页码：740 / 743
页数：4
相关论文
共 50 条
  • [21] Serum CA19-9 determination in the management of pancreatic cancer
    vandenBosch, RP
    vanEijck, CHJ
    Mulder, PGH
    Jeekel, J
    HEPATO-GASTROENTEROLOGY, 1996, 43 (09) : 710 - 713
  • [22] Clinical usefulness of CA19-9 for the screening of pancreatic cancer in asymptomatic subjects.
    Lee, KT
    Rhee, PL
    Kim, J
    Koh, JC
    Paik, SW
    Rhee, JC
    Shin, MH
    GASTROENTEROLOGY, 1997, 112 (04) : A457 - A457
  • [23] CA19-9 as a Predictor of Resectability in Patients with Pancreatic Cancer
    He, Z.
    Lu, H.
    Hu, W.
    Tian, B.
    Zhang, Z.
    PANCREAS, 2011, 40 (08) : 1326 - 1326
  • [24] Prognostic value of CA19-9 in patients with pancreatic adenocarcinoma after chemoradiotherapy
    Nampei, Y.
    Toyomasu, Y.
    Ochiai, S.
    Mase, T.
    Watanabe, Y.
    Kawamura, T.
    Takada, A.
    Yamashita, Y.
    Li, N.
    Sakuma, H.
    Nomoto, Y.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S568 - S569
  • [25] Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer
    Reitz, Daniel
    Gerger, Armin
    Seidel, Julia
    Kornprat, Peter
    Samonigg, Hellmut
    Stotz, Michael
    Szkandera, Joanna
    Pichler, Martin
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (06) : 427 - 433
  • [26] Clinical significance of serum LDH, CEA and CA19-9 levels in metastatic pancreatic cancer
    Karabulut, S.
    Ciftci, R.
    Sen, F.
    Tas, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S601 - S602
  • [27] The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice
    Engle, Dannielle D.
    Tiriac, Herve
    Rivera, Keith D.
    Pommier, Arnaud
    Whalen, Sean
    Oni, Tobiloba E.
    Alagesan, Brinda
    Lee, Eun Jung
    Yao, Melissa A.
    Lucito, Matthew S.
    Spielman, Benjamin
    Da Silva, Brandon
    Schoepfer, Christina
    Wright, Kevin
    Creighton, Brianna
    Afinowicz, Lauren
    Yu, Kenneth H.
    Gruetzmann, Robert
    Aust, Daniela
    Gimotty, Phyllis A.
    Pollard, Katherine S.
    Hruban, Ralph H.
    Goggins, Michael G.
    Pilarsky, Christian
    Park, Youngkyu
    Pappin, Darryl J.
    Hollingsworth, Michael A.
    Tuveson, David A.
    SCIENCE, 2019, 364 (6446) : 1156 - +
  • [28] The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer
    Mansson, Christopher
    Nilsson, Anders
    Urdzik, Jozef
    Karlson, Britt-Marie
    ANTICANCER RESEARCH, 2019, 39 (11) : 6193 - 6196
  • [29] Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
    Lakemeyer, Leilani
    Sander, Silvia
    Wittau, Mathias
    Henne-Bruns, Doris
    Kornmann, Marko
    Lemke, Johannes
    DISEASES, 2021, 9 (01)
  • [30] Prognostic and predictive value of CA19-9 in metastatic colorectal cancer
    Narita, Yukiya
    Taniguchi, Hiroya
    Komori, Azusa
    Nitta, Sohhei
    Yamaguchi, Kazuhisa
    Kondoh, Chihiro
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
12345